228 related articles for article (PubMed ID: 37076096)
1. Clot waveform analysis for perioperative hemostatic monitoring in a hemophilia A patient on emicizumab undergoing liver transplantation.
Awane M; Wakui M; Ozaki Y; Kondo Y; Oka S; Fujimori Y; Yatabe Y; Arai T; Yamada Y; Hori S; Obara H; Hasegawa Y; Matsushita H
Clin Chim Acta; 2023 Apr; 544():117339. PubMed ID: 37076096
[TBL] [Abstract][Full Text] [Related]
2. Modified clot waveform analysis to measure plasma coagulation potential in the presence of the anti-factor IXa/factor X bispecific antibody emicizumab.
Nogami K; Matsumoto T; Tabuchi Y; Soeda T; Arai N; Kitazawa T; Shima M
J Thromb Haemost; 2018 Jun; 16(6):1078-1088. PubMed ID: 29645406
[TBL] [Abstract][Full Text] [Related]
3. Anti-idiotype monoclonal antibodies against emicizumab enable accurate procoagulant and anticoagulant assays, irrespective of the test base, in the presence of emicizumab.
Ogiwara K; Furukawa S; Shinohara S; Tabuchi Y; Arai N; Noguchi-Sasaki M; Soeda T; Shima M; Nogami K
Haemophilia; 2023 Jan; 29(1):329-335. PubMed ID: 36137299
[TBL] [Abstract][Full Text] [Related]
4. Routine measurements of factor VIII activity and inhibitor titer in the presence of emicizumab utilizing anti-idiotype monoclonal antibodies.
Nogami K; Soeda T; Matsumoto T; Kawabe Y; Kitazawa T; Shima M
J Thromb Haemost; 2018 Jul; 16(7):1383-1390. PubMed ID: 29734520
[TBL] [Abstract][Full Text] [Related]
5. Effects of emicizumab on APTT, one-stage and chromogenic assays of factor VIII in artificially spiked plasma and in samples from haemophilia A patients with inhibitors.
Bowyer A; Kitchen S; Maclean R
Haemophilia; 2020 May; 26(3):536-542. PubMed ID: 32249990
[TBL] [Abstract][Full Text] [Related]
6. Laboratory Monitoring in Emicizumab-Treated Persons with Hemophilia A.
Müller J; Pekrul I; Pötzsch B; Berning B; Oldenburg J; Spannagl M
Thromb Haemost; 2019 Sep; 119(9):1384-1393. PubMed ID: 31203578
[TBL] [Abstract][Full Text] [Related]
7. Novel Insights and New Developments Regarding Coagulation Revealed by Studies of the Anti-Factor IXa (Activated Factor IX)/Factor X Bispecific Antibody, Emicizumab.
Yada K; Nogami K
Arterioscler Thromb Vasc Biol; 2020 May; 40(5):1148-1154. PubMed ID: 32237902
[TBL] [Abstract][Full Text] [Related]
8. The Evaluation of Clot Waveform Analyses for Assessing Hypercoagulability in Patients Treated with Factor VIII Concentrate.
Matsumoto T; Wada H; Shiraki K; Suzuki K; Yamashita Y; Tawara I; Shimpo H; Shimaoka M
J Clin Med; 2023 Sep; 12(19):. PubMed ID: 37834964
[TBL] [Abstract][Full Text] [Related]
9. A Clot Waveform Analysis of Thrombin Time Using a Small Amount of Thrombin Is Useful for Evaluating the Clotting Activity of Plasma Independent of the Presence of Emicizumab.
Wada H; Shiraki K; Matsumoto T; Suzuki K; Yamashita Y; Tawara I; Shimpo H; Shimaoka M
J Clin Med; 2022 Oct; 11(20):. PubMed ID: 36294464
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics and Pharmacodynamics of Emicizumab in Persons with Hemophilia A with Factor VIII Inhibitors: HAVEN 1 Study.
Schmitt C; Adamkewicz JI; Xu J; Petry C; Catalani O; Young G; Negrier C; Callaghan MU; Levy GG
Thromb Haemost; 2021 Mar; 121(3):351-360. PubMed ID: 33086400
[TBL] [Abstract][Full Text] [Related]
11. [Emicizumab: a paradigm shift in hemophilia treatment].
Nogami K
Rinsho Ketsueki; 2020; 61(5):536-541. PubMed ID: 32507821
[TBL] [Abstract][Full Text] [Related]
12. Intrinsic differences between FVIIIa mimetic bispecific antibodies and FVIII prevent assignment of FVIII-equivalence.
Leksa NC; Aleman MM; Goodman AG; Rabinovich D; Peters R; Salas J
J Thromb Haemost; 2019 Jul; 17(7):1044-1052. PubMed ID: 30887655
[TBL] [Abstract][Full Text] [Related]
13. Clot waveform analysis for perioperative hemostatic monitoring of arthroscopic synovectomy in a pediatric patient with hemophilia A and inhibitor receiving emicizumab prophylaxis.
Mizumachi K; Tsumura Y; Nakajima Y; Koh K; Nogami K
Int J Hematol; 2021 Jun; 113(6):930-935. PubMed ID: 33566316
[TBL] [Abstract][Full Text] [Related]
14. Effects and Interferences of Emicizumab, a Humanised Bispecific Antibody Mimicking Activated Factor VIII Cofactor Function, on Coagulation Assays.
Adamkewicz JI; Chen DC; Paz-Priel I
Thromb Haemost; 2019 Jul; 119(7):1084-1093. PubMed ID: 31064025
[TBL] [Abstract][Full Text] [Related]
15. Emicizumab, the bispecific antibody to factors IX/IXa and X/Xa, potentiates coagulation function in factor XI-deficient plasma in vitro.
Minami H; Nogami K; Yada K; Ogiwara K; Furukawa S; Soeda T; Kitazawa T; Shima M
J Thromb Haemost; 2019 Jan; 17(1):126-137. PubMed ID: 30444568
[TBL] [Abstract][Full Text] [Related]
16. A modified thrombin generation assay to evaluate the plasma coagulation potential in the presence of emicizumab, the bispecific antibody to factors IXa/X.
Ogiwara K; Nogami K; Matsumoto N; Noguchi-Sasaki M; Hirata M; Soeda T; Shima M
Int J Hematol; 2020 Nov; 112(5):621-630. PubMed ID: 32748217
[TBL] [Abstract][Full Text] [Related]
17. Chromogenic Factor VIII Assay for Patients with Hemophilia A and on Emicizumab Therapy.
Yacoub OA; Duncan EM
Methods Mol Biol; 2023; 2663():597-610. PubMed ID: 37204739
[TBL] [Abstract][Full Text] [Related]
18. Emicizumab for routine prophylaxis to prevent bleeding episodes in patients with hemophilia A.
Díaz-Ricart M; Isola IM; Escolar G
Drugs Today (Barc); 2018 Oct; 54(10):591-600. PubMed ID: 30398480
[TBL] [Abstract][Full Text] [Related]
19. Emicizumab improves the stability and structure of fibrin clot derived from factor VIII-deficient plasma, similar to the addition of factor VIII.
Shimonishi N; Nogami K; Ogiwara K; Matsumoto T; Nakazawa F; Soeda T; Hirata M; Arai N; Shima M
Haemophilia; 2020 May; 26(3):e97-e105. PubMed ID: 32157756
[TBL] [Abstract][Full Text] [Related]
20. Effects of Emicizumab on APTT, FVIII assays and FVIII Inhibitor assays using different reagents: Results of a UK NEQAS proficiency testing exercise.
Lowe A; Kitchen S; Jennings I; Kitchen DP; Woods TAL; Walker ID
Haemophilia; 2020 Nov; 26(6):1087-1091. PubMed ID: 33094895
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
